Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
This formulation achieved 20.7% weight loss in trials, narrowing the gap between existing Ozempic/Wegovy and Retatrutide
N Engl J Med 373(23):22472257
In a placebo-controlled trial, weekly subcutaneous semaglutide led to larger reductions in BMI (16.1% with semaglutide and +0.6% with placebo), body weight (15.3 kg with semaglutide and +2.4 kg with placebo), waist circumference, glycated hemoglobin levels, lipid parameters (excluding HDL), and alanine aminotransferase at 68 weeks versus placebo [14]
External resources For researchers serious about optimizing their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, dosing calculators, and a community of thousands who have navigated these exact questions
Hobart notes that many people report improvements in depressive symptoms following weight loss itself, even without the use of GLP-1 medications
